Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma
The purpose of this study is to test whether it is safe to give Galinpepimut-S and Nivolumab together in patients with mesothelioma.
Mesothelioma|Pleural Mesothelioma|Wilms Tumor
BIOLOGICAL: Galinpepimut-S|DRUG: Nivolumab|BIOLOGICAL: Sargramostim
Maximum tolerated dose, A dose will be considered tolerable if there are no more than 2 out of 10 participants with dose limiting toxicities., up to 24 months
The purpose of this study is to test whether it is safe to give Galinpepimut-S and Nivolumab together in patients with mesothelioma.